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Introduction

Conclusion

Tumor cells grow in nutrient and oxygen deprived microenvironments
and adapt to the suboptimal growth conditions by altering metabolic
pathways. This adaptation process characteristically results in a tumor
phenotype that displays anaerobic glycolysis, chronic acidification
and aggressive tumor characteristics. Understanding the tumor cell
reaction to the microenvironment is a critical factor in predicting the
tumor response to hyperthermia. The glucose regulatory molecule,
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase Isoform-3
(PFKFB3), is a bifunctional enzyme central to glycolytic flux and
downstream of the metabolic stress sensor AMP-activated protein
kinase (AMPK), which has been shown to activate an isoform of
Phosphofructokinase (PFK-2).

These results indicate that growth at tumor-like low pH activates
AMPK and induces a high glycolytic and apoptotic potential that is
countered by TIGAR and anti-apoptotic proteins, respectively. The
control of glycolysis can thus minimize acidification and further
protect tumor cells from death. These metabolic pathways in response
to the microenvironment need to be incorporated in hyperthermia
treatment strategies.
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Results
As hypothesized, our results demonstrated that exposure to chronic
low pH induced AMPK activation which resulted in the upregulation
of PFKFB3 and p53, and the downregulation of mammalian TargetOf-Rapamycin (mTOR) in two tumor cell lines, DB-1 human
melanoma and U87 human glioma. Conversely, inhibition of
AMPK resulted in downregulation of PFKFB3 and inhibition of
glycolysis. When PFKFB3 was over-expressed in DB-1 melanoma, it
induced a high rate of glycolysis and inhibited oxygen consumption.
By contrast, cells adapted to growth at low pH did not display an
increased rate of glycolysis after PFKFB3 induction because the level
of the TP53-induced Glycolysis and Apoptosis Regulator (TIGAR)
was increased. Low pH adapted cells also were resistant to apoptosis,
despite upregulation of p53. This may be partially explained by the
induction of anti-apoptotic proteins and TIGAR’s ability to reduce
lactate production.
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